A study recently published in the journal European Respiratory Review reported the case of a man with pulmonary hypertension resulting from silica exposure-induced sarcoidosis. The report urges clinicians to be aware of this rare cause of pulmonary hypertension, in which specific analyses are needed to confirm a diagnosis.
News
Results from a retrospective study based on a claims database of U.S. patients with pulmonary embolism indicated that physicians are failing to recognize and diagnose thousands of cases of a serious lung disease, chronic thromboembolic pulmonary hypertension (CTEPH). The study, “Monitoring for Pulmonary Hypertension Following Pulmonary Embolism: The INFORM…
Iloprost, an inhaled solution, is approved for the management of pulmonary arterial hypertension (PAH) in several countries, including the United States. A new study explored the drug’s effects in a Japanese population and found it to be both efficient and safe, a finding echoing results of previous studies largely conducted in…
A scientist from the Montreal Heart Institute (MHI) recently presented the results of a Phase 2 clinical trial demonstrating PulmoBind biomarker’s safety and the PulmoBind tomography (SPECT) scan’s ability to detect abnormalities in pulmonary hypertension (PH) patients . The presentation was made at the Annual Meeting of the…
The Committee for Medicinal Products for Human Use (CHMP), the scientific board of the European Medicines Agency (EMA), has “readopted” its positive opinion in support of Actelion’s Uptravi (selexipag) as a treatment for pulmonary arterial hypertension (PAH). According to an Actelion press release, the “re-adoption” of the…
The Pulmonary Hypertension Association (PHA) recently announced the accreditation of two new Centers of Comprehensive Care and their inclusion in its Pulmonary Hypertension Care Centers (PHCC) initiative. PHA comprehensive care centers can now be found in 23 U.S. states, assisting and providing more treatment options for adults and children…
Pediatric Cardiologist Marlene Rabinovitch Honored for Life’s Work on PH and Heart Disease Research
Marlene Rabinovitch, MD, a pediatric cardiology physician at Stanford Children’s Health and Lucile Packard Children’s Hospital Stanford, will be honored for her life’s work and present the 2016 J. Burns Amberson Lecture at the American Thoracic Society (ATS)’s Annual Meeting, which will take place in San Francisco on May…
The use of a combination therapy in patients with pulmonary arterial hypertension (PAH) “significantly” reduced the risk of clinical worsening compared to monotherapy in those responding to treatment, according to a recent meta-analysis published in the journal The Lancet, titled “Combination therapy versus monotherapy for pulmonary arterial hypertension:…
Researchers recently investigated the link between thyroid gland function and idiopathic pulmonary hypertension, finding subclinical hypothyroidism in almost half of patients observed. The study, “Assessment of Thyroid Function in Idiopathic Pulmonary Hypertension,” was published in the Research in Cardiovascular Medicine journal. Idiopathic pulmonary hypertension is a rare and ultimately fatal…
Experimental PH Treatment, Ubenimex, Recognized as Orphan Drug by EMA in Advance of Clinical Study
Eiger BioPharmaceuticals recently announced that its protease inhibitor ubenimex has been granted Orphan Medicinal Product designation by the European Medicines Agency (EMA) for the treatment of pulmonary arterial hypertension (PAH). The company will soon begin a Phase 2 clinical trial testing ubenimex in this patient group. The EMA designation covers…
People with chronic thromboembolic pulmonary hypertension (CTEPH) show an increased prevalence of sleep disordered breathing, a condition predicted by low cardiac index, according to the study “Usefulness of Low Cardiac Index to Predict Sleep-Disordered Breathing in Chronic Thromboembolic Pulmonary Hypertension,” published in the American Journal…
Pulmonary Rehab of Multiple Benefit to People with PH and Other Respiratory Diseases, Release Notes
Pulmonary rehabilitation has been shown to significantly improve the quality of life of those affected by lung diseases, including chronic obstructive pulmonary disease (COPD), interstitial pulmonary fibrosis (IPF), or pulmonary hypertension (PH), a University of Kentucky news release reported. But what, exactly, is pulmonary rehabilitation? The American Association of…
Recent Posts
- Signaling molecule in exosomes may limit PAH right-heart damage
- Researchers test cellular ‘shipping containers’ for use in PH treatment
- Misuse of assistive services makes it harder to travel with a disability
- Sit-to-stand chair test may predict adverse outcomes in PH: Study
- New study links SOX17 mutations to severe PAH in children, some adults
